Comparative Reconstruction of SARS-CoV-2 transmission in three African countries using a mathematical model integrating immunity data.
暂无分享,去创建一个
Walid Ben Aribi | S. Miled | K. Dellagi | I. Vigan-Womas | M. Diarra | M. Schoenhals | A. Kebir | bechir neffeti
[1] Reed J. D. Sorensen,et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis , 2023, The Lancet.
[2] Sébastien Bourdin,et al. Spatio-temporal evolution of the COVID-19 across African countries , 2022, Frontiers in Public Health.
[3] O. Faye,et al. First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics , 2022, PloS one.
[4] M. Hsairi,et al. Hospital bed capacity across in Tunisia hospital during the first 4 waves of the COVID-19 pandemic: A descriptive analysis , 2022, Infectious Medicine.
[5] H. Triki,et al. Molecular Epidemiology of SARS-CoV-2 in Tunisia (North Africa) through Several Successive Waves of COVID-19 , 2022, Viruses.
[6] Z. Randriamanantany,et al. Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors , 2021, The Lancet Global Health.
[7] A. Fontanet,et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection , 2021, EBioMedicine.
[8] Saúl Pérez-González,et al. Epidemiological models and COVID-19: a comparative view , 2021, History and Philosophy of the Life Sciences.
[9] J. Héraud,et al. SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic , 2021, EBioMedicine.
[10] Hannah Ritchie,et al. A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.
[11] Y. Kawaoka,et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months , 2021, EClinicalMedicine.
[12] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[13] S. Jordan,et al. Innate and adaptive immune responses to SARS‐CoV‐2 in humans: relevance to acquired immunity and vaccine responses , 2020, Clinical and experimental immunology.
[14] M. Nussenzweig,et al. Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.
[15] A. Iafrate,et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.
[16] J. Scott,et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.
[17] Otto O. Yang,et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.
[18] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[19] Sang Woo Park,et al. Modeling shield immunity to reduce COVID-19 epidemic spread , 2020, Nature Medicine.
[20] R. Berisio,et al. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping , 2020, Cells.
[21] Gergely Röst,et al. Temporal evolution of immunity distributions in a population with waning and boosting , 2018, bioRxiv.
[22] M. Buchmeier,et al. Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.
[23] L. White,et al. Microparasite population dynamics and continuous immunity , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.